How Your Body Senses Cold—And Why Menthol Feels Cool
Researchers used cryo‑electron microscopy to capture multiple conformational states of the cold‑sensing ion channel TRPM8 as it transitions from closed to open. The study revealed that actual cold and menthol trigger the channel through overlapping yet distinct allosteric pathways, with cold acting on the pore region and menthol binding elsewhere. Combined cold and menthol produce a synergistic opening, enabling the first structural view of the fully open channel. The findings have medical relevance, informing therapies such as the TRPM8‑activating eye drop Acoltremon and potential treatments for pain, migraines, and dry eye.
Sometimes Less Is More: Messier Nanoparticles May Actually Deliver Drugs More Effectively than Tightly Packed Ones
Researchers at the University of Copenhagen unveiled a high‑throughput, single‑nanoparticle analysis that examined millions of lipid nanoparticles (LNPs) used for RNA delivery. The study identified two distinct LNP subpopulations—organized, onion‑layered particles and disordered, amorphous particles—and found the latter release their...

It Seems Bad That Temu Is Selling Peptides
A recent Futurism report reveals that the low‑cost e‑commerce platform Temu is selling a variety of peptide products, including BPC‑157 and GLP‑1‑like compounds, at prices as low as $4. These peptides, marketed as muscle, skin, or cognitive boosters, are often...
GLP-1 Drugs Fail to Slow Cognitive Decline in Alzheimer’s Disease
Recent randomized trials testing GLP‑1 receptor agonists such as semaglutide and liraglutide in Alzheimer’s disease patients found no measurable slowing of cognitive decline. Earlier post‑hoc and observational analyses had suggested roughly a 50 % reduction in dementia incidence, raising hopes of...
Science Corp. And Neurosoft Bioelectronics Announce Novel BCI Ecosystem Partnership
Science Corporation and Neurosoft Bioelectronics have signed a multiyear, multimillion‑dollar partnership granting Neurosoft access to Science’s full‑stack clinical‑grade BCI tools, known as the Science BCI Ecosystem. The deal lets Neurosoft develop minimally invasive, fully implantable brain‑computer interfaces for tinnitus, epilepsy...
What Is a 'Seesaw Protein' That Switches Functions by Changing Shape?
Researchers at the Institute of Science Tokyo have engineered an artificial "seesaw protein" that alternates between a fluorescent marker and an enzymatic catalyst. The switch is controlled by a single amino‑acid change, pH shifts, or ligand binding, and only one...
Learning From FDA’s Moderna U-Turn
The FDA abruptly reversed its decision to approve Moderna’s mRNA‑based flu vaccine after the White House intervened, sparking intense discussion in biotech boardrooms. The reversal was driven by political considerations rather than new scientific data, underscoring the agency’s vulnerability to...
Novartis Breaks Ground on $23B Biomedical Research Hub in San Diego
Novartis began construction of a new biomedical research hub in San Diego. The 466,000‑sq‑ft center, part of a $23 billion US R&D and manufacturing program, will house about 1,000 researchers and target neuroscience, oncology, global health, and age‑related diseases. Scheduled to...
How to Avoid a Fall by Balancing Cost and Performance in Drug Discovery
Balancing cost and performance in drug discovery requires a hybrid engineering‑led approach that combines on‑premise HPC with scalable cloud resources. Uncontrolled cloud scaling can drive unpredictable expenses, while pure on‑premise systems demand high upfront capital and maintenance. By implementing disciplined...
Altesa BioSciences Raises $75M Series B
Altesa BioSciences announced an oversubscribed $75 million Series B round, led by Forbion with participation from Sanofi and existing backers Medicxi, Pitango, and Atlantic Partners. The financing will support the development of its lead candidate, vapendavir, targeting viral-driven exacerbations in COPD and...
Topical Adquey (Difamilast) Wins FDA Approval for Atopic Dermatitis
The U.S. Food and Drug Administration has granted approval to Adquey, a 1% difamilast topical ointment, for the treatment of mild-to-moderate atopic dermatitis in patients two years and older. Developed by Otsuka and licensed to Acrotech Biopharma, the product is...
5-Day Preoperative Radiotherapy in High-Risk STS Shows Manageable Toxicity
A phase‑2 single‑center trial evaluated a five‑day pre‑operative radiotherapy schedule in 110 patients with high‑risk soft‑tissue sarcoma. At two‑year follow‑up, grade ≥ 2 radiation‑related toxicities were observed in 14 of 74 evaluable patients, with lower rates in the extension cohort. Major wound...
At an Inflection Point in HIV Science: Nicolas Chomont, PhD, Looks Ahead to CROI 2026
Nicolas Chomont, chair of CROI 2026’s scientific program, previewed the conference’s focus on emerging HIV research, including treatment, cure, and vaccine advances. The meeting will showcase extensive data on long‑acting antiretroviral therapies and address funding constraints affecting global HIV initiatives....
Ten63 Therapeutics Secures New Funding
Ten63 Therapeutics, an AI‑driven drug‑discovery firm spun out of Duke and TTIC, announced a strategic investment from Chugai Venture Fund and the Bill & Melinda Gates Foundation, bringing total capital to over $45 million. The company leverages its BEYOND generative‑chemistry platform...
FDA Cracks Down as Novo Sues Hims over Semaglutide
This is the first reference which I heard directly from FDA commissioner Dr. Marty Makary regarding $HIMS, $NVO 🧵👇and the recent legal actions that the HHS had initiated against HIMs and Hers. When he was asked by @annikakimc - @CNBC’s...
Hormone-Regulated Immune Cells Implicated in Longer Lasting Pain in Women
Researchers at Michigan State University discovered that hormone‑regulated monocytes producing interleukin‑10 (IL‑10) drive faster pain resolution in males. In mouse models, testosterone‑dependent IL‑10+ monocytes cleared inflammatory pain more quickly, while females exhibited fewer of these cells and prolonged pain. Human...
To What Degree Does Cytomegalovirus Contribute to Neurodegenerative Conditions?
Cytomegalovirus (CMV) infection, prevalent in most adults, increasingly appears linked to neurodegenerative processes. Large cohort studies show higher CMV IgG levels correlate with accelerated cognitive decline, and post‑mortem analyses detect CMV DNA in a majority of vascular dementia brains. Animal...
New Insights Into How Bacteria Control DNA Synthesis Open the Door to Next Generation Antimicrobials
Researchers have solved the crystal structure of the bacterial transcriptional regulator NrdR and shown how its assembly shifts in response to ATP and dATP, directly controlling ribonucleotide reductase (RNR) gene expression. The work, performed on Escherichia coli and Pseudomonas aeruginosa,...

Kansas City Launches Integrated Theranostics Platform Partnership
A public‑private partnership between the University of Kansas Health System, KU Medical Center, Children’s Mercy and Bold Advanced Medical Future (BAMF) Health is launching an integrated theranostics platform in Kansas City. The center will combine molecular imaging, radiopharmaceutical production, clinical...
In the Clinic for Feb. 20, 2026
The February 20 2026 "In the Clinic" roundup aggregates a broad set of industry snapshots, special reports, and infographics covering biopharma, medical technology, and emerging research areas. It links to data on mRNA vaccine research, China’s GLP‑1 market, pulsed‑field ablation for atrial...

Generic Drugs Forum (GDF) 2026 - 04/22/2026
On April 22‑23, 2026, the FDA’s Center for Drug Evaluation and Research hosted the annual Generic Drugs Forum at its White Oak Campus, with a virtual option via Adobe Connect. The two‑day event gathered generic drug developers, consultants, and regulatory...
Macrophage Phenotype–Dependent Protein Corona Formation Governs Ligand Accessibility and Immune Clearance of Biomimetic Nanoparticles
Researchers coated magnetic silica nanoparticles with membranes from naïve (M0), classically activated (M1) and alternatively activated (M2) macrophages to study phenotype‑dependent protein corona formation. Proteomic analysis showed M0‑derived membranes adsorbed the fewest opsonins (C3, IgG, IgM) and triggered the lowest...
From Junk Science (Largely Non-Political) to Junk Medical Treatments (Mostly Associated with the Far-Right): A Financial Connection
Paul Krugman highlights a growing financial link between the multi‑billion‑dollar wellness industry and right‑wing extremist movements. He notes that U.S. spending on wellness reaches roughly $500 billion annually, with nutritional supplements alone accounting for about $70 billion, while regulators like the FDA...
A Quercetin Nanocarrier‐Loaded Dual Network Injectable Hydrogel for Mesenchymal Stem Cells (MSCs) Delivery Targeting Osteoarthritis
Researchers have created an injectable dual‑network hydrogel composed of gelatin methacrylate and κ‑carrageenan that embeds quercetin‑loaded PLGA nanoparticles for mesenchymal stem cell (MSC) delivery in osteoarthritis (OA). The antioxidant hydrogel scavenges reactive oxygen species, reprograms M1 macrophages to an anti‑inflammatory...

STAT+: Pharmalittle: We’re Reading About an FDA Official’s Speech, a Grail Cancer Blood Test, and Much More
FDA drug‑center head Tracy Beth Høeg used her first staff address to flag two priority areas: the safety of antidepressants taken during pregnancy and the use of monoclonal antibodies that protect infants from RSV. She also signaled a continued interest...
Exercise‑induced Liver Enzyme GPLD1 Restores Memory, Boosts Vascular Health
Liver enzyme GPLD1 produced during exercise reverses aging- and Alzheimer’s-related memory loss by improving vascular health https://www.cell.com/cell/fulltext/S0092-8674%2826%2900111-X

FDA Starts Review of Regeneron's Drug for Rare Disease FOP
The FDA has placed Regeneron's anti‑activin A antibody garetosmab under priority review, with a decision expected by August. Phase 3 OPTIMA data showed a 94% reduction in new heterotopic ossification lesions at the lower dose and a 90% reduction at the higher...

Inside Oxford’s Biotech Hub: A Scientific Powerhouse Situated in the U.K.’s Golden Triangle
Oxford has cemented its status as a leading European biotech hub, anchored by the University of Oxford’s deep biomedical expertise and a thriving spin‑out ecosystem. The Oxford Science Park now houses nearly 100 life‑science companies, while the £1.2 bn Oxford North...
Evolving Frontline Treatment Strategies in Diffuse Large B-Cell Lymphoma
Frontline treatment of diffuse large B‑cell lymphoma (DLBCL) is shifting from traditional R‑CHOP toward targeted and bispecific antibody‑based regimens. The POLARIX phase‑3 trial demonstrated that Pola‑R‑CHP improves progression‑free survival, particularly in activated‑B‑cell (ABC) disease and older patients. Early phase studies...

Nanozyme Aptasensor: A Breakthrough in S. Aureus Diagnostics
Researchers have unveiled a nanozyme‑aptamer colorimetric array that classifies Staphylococcus aureus strains with 100% accuracy, including methicillin‑resistant variants. The platform couples gold‑nanoparticle nanozymes with four strain‑specific aptamers, producing distinct color fingerprints that are decoded by hierarchical clustering and linear discriminant...
No One-Trick Pony in Oncology, Merck’s Cancer Footprint Is Expanding
Merck is expanding beyond its flagship Keytruda by investing in diverse oncology platforms. In 2024 it spent $700 million on a bispecific candidate from Curon and $680 million to acquire Harpoon Therapeutics, bolstering its T‑cell engager portfolio. The company is also advancing...

FDA Approves Acalabrutinib with Venetoclax for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The FDA approved a fixed‑dose combination of acalabrutinib (Calquence) and venetoclax (Venclexta) for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The decision is based on the AMPLIFY trial, which showed a 35% reduction in progression‑free survival risk compared...

The US FDA Accepts Roche’s Giredestrant NDA for ESR1-Mutated, ER-Positive Advanced Breast Cancer
The U.S. FDA has accepted Roche’s new drug application for giredestrant combined with everolimus to treat ER‑positive, HER2‑negative, ESR1‑mutated advanced breast cancer. Phase III evERA data show a 44% reduction in disease progression or death overall and a 62% reduction in...

UK Firm Steps in to Ease Medicine Supply Crisis in NHS
A shortage of bone cement from German supplier Heraeus Medical threatens NHS orthopaedic surgeries, potentially lasting two months. NHS England has asked trusts to prioritise emergency joint replacements, leaving elective patients at risk. UK‑based Biocomposites accelerated the launch of its...

Novartis to Divest India Unit to Private Equity-Led Consortium for $159M
Novartis announced the sale of its majority stake in its Indian generics and prescription business to a private‑equity‑led consortium for $159 million. The transaction transfers control of a portfolio that includes both off‑patent generics and branded medicines to the buyers. The...
Revealing Remarkable Genomic Architecture in Embryonic Reproductive Cells Prior to Sperm and Egg Development
Researchers led by Dr. Tien‑Chi Huang discovered a dramatic three‑dimensional reorganization of genome architecture in mouse and human embryonic germ cells as they enter meiosis. Centromeres relocate from the nuclear interior to the periphery, accompanied by reduced compartmentalization and increased...
Levetiracetam Reduces Amyloid-Β Production in the Brain
Researchers report that the FDA‑approved antiepileptic levetiracetam reduces amyloid‑β42 production in mouse models of Alzheimer’s disease. The drug redirects amyloid precursor protein processing toward the non‑amyloidogenic pathway by modifying synaptic vesicle cycling and increasing surface APP expression. Mass‑spectrometry and electrophysiology...
Aging Is Often Overlooked in Mouse Models of Age-Related Conditions
Researchers increasingly rely on rapid, toxic mouse models that sideline the natural aging process, even though age is the chief risk factor for many diseases. In Parkinson's disease research, most pre‑clinical studies still use young rodents, obscuring how biological aging...

Pharma Pulse: J&J’s $1B Cell Therapy Hub and Hims & Hers’ Global Expansion
Johnson & Johnson announced a $1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Montgomery County, Pennsylvania, slated to support 500 skilled jobs. The hub is a key element of J&J’s $55 billion U.S. manufacturing, R&D, and technology strategy. Meanwhile,...
NKTR’s Alopecia Areata Play: Market Misprices Massive Upside
Ok, so I have finally gotten around to writing out my updated thoughts/thesis on $NKTR. Link in this post. I'm about as bullish on the stock now as I've ever been. The document is very long (sorry, but it's free...give me...
Monocyte IL‑10 Explains Sex Differences in Pain Duration
Sex differences in pain duration Finding interleukin-10 from monocytes as an/the explanation (in the experimental model and people) @SciImmunology https://t.co/fOsciwav7Y

Ex-Novartis CMO John Tsai Joins Daiichi Sankyo
Daiichi Sankyo appointed former Novartis chief medical officer John Tsai as its new CMO, succeeding Ken Takeshita after a five‑year tenure. Tsai brings a record of launching 160 projects and 15 regulatory approvals, including Zolgensma and Pluvicto, and recent experience leading biotech...

Nasal Mucosa Targeted for Universal Respiratory Vaccine
How to get a universal vaccine vs respiratory threats? Block via the nasal mucosa @ScienceMagazine https://t.co/IjCkbF05LB @NatRevImmunol https://t.co/2W7SZ1fHSR https://t.co/XcEzcMeXrB
New Drug Discoveries Target Cancer and Autoimmunity
Discovering Drugs for Cancer and Autoimmunity. Listen to @Satpathology on The Long Run podcast. Sponsored by @AlphaSenseInc Dash Bio. https://t.co/02keVFdqzj

NexEos Bio Receives US FDA IND Clearance to Advance NTX-1024 Into P-II/III Study for Vernal Keratoconjunctivitis
U.S. FDA has granted IND clearance for NexEos Bio’s ophthalmic solution NTX-1024, allowing the company to commence a combined Phase II/III clinical trial in vernal keratoconjunctivitis (VKC). The upcoming study will assess safety and efficacy after an open‑label investigator‑initiated trial...
Lymphopenia Reversal Won’t Secure Anktiva FDA Approval
Reversal of lymphopenia is not an acceptable endpoint for Anktiva FDA approval. $IBRX could file but if it did, the application would be rejected.

Cyborg Islet-Cell Implant Boosts Precision Diabetes Therapy
A cyborg pancreatic islet-cell implant takes the stem cell strategy to a new level of precision and potential future therapy for T1 diabetes @ScienceMagazine https://t.co/gkmsrzU1e4 https://t.co/qgegRPlEIl

Neutrophil Phenotypes and Spatial Patterns Mapped in Colorectal Cancer
Single-cell integration and multi-modal profiling reveals phenotypes and spatial organization of neutrophils in colorectal cancer https://t.co/0FLusa7vuB https://t.co/8MswWoLhCa

Screening Cuts Advanced Colon Cancer, Boosts Early Detection
Screening works for colon cancer. Largest trial ever done. Today @NatureMedicine A randomized trial of colon cancer screening by colonoscopy or occult blood (FIT) vs control in nearly 280,000 participants showed signficantly more early diagnosis (stage I-II) and less stage...
AZN's Calquence + Venetoclax Approved for CLL Treatment
#AZN Calquence combined with Venetoclax approved in US for treating Adults with Chronic Lymphocytic Leukaemia in a particular form.